Executive Chairman and CEO Graham Kelly discusses how Noxopharm (ASX: NXO) are developing the next generation of anti-cancer drugs, called Veyonda. During this highly interesting session, Graham shares the promising results of the Phase 1 Study targeting prostate cancer, the plan to develop more impactful studies, and why the Company is well positioned in keys markets.

Noxopharm is an Australian-based, clinical stage drug development company which focuses on two areas of drug technology: the potential benefit to cancer patients in being able to increase their responsiveness to standard of care chemotherapies and radiotherapies; and the technology behind Veyonda and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.

Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

Accurate time of recording, 8 July 2020 at 12pm AEST.